Beijing Rejing Biologicals first sale of repurchased shares, 9,100 shares traded for over 1.15 million yuan

Log in to the Sina Finance app and search for 【Information Disclosure】to view more evaluation tiers

Beijing Rejing Biotechnology Co., Ltd. (hereinafter referred to as “Rejing Bio”) announced on April 1, 2026 that the company had, on March 30, for the first time sold the repurchased shares through centralized bidding transactions. The number of shares sold was 9,100 shares. The total transaction amount was approximately 1,156.67 yuan (ten thousand yuan) (RMB 1.1567 million), and the average price was 127.11 yuan per share. This sale marks that the company’s plan for disposing of repurchased shares has officially entered the implementation phase.

Background of the repurchase: previously spent to repurchase 2.893 million shares

According to the announcement, in order to maintain the company’s value and protect the interests of its shareholders, Rejing Bio carried out share repurchases between February 8 and May 7, 2024. A total of 289.301 million shares were repurchased, accounting for 3.12% of the company’s current total share capital. In accordance with relevant regulations, the above repurchased shares must be sold through centralized bidding transactions within 12 months after the announcement of the results of the share repurchase and the announcement on changes in shares; if the plan is not implemented within 36 months after the completion of the repurchase, the unused portion must be cancelled.

Sale plan: intends to sell no more than 1.8542 million shares within six months

On December 23, 2025, Rejing Bio’s 4th session of the Board of Directors’ 8th meeting considered and approved a proposal to sell part of the repurchased shares. The board agreed that, within six months after 15 trading days from the date of disclosure of the sale plan (i.e., from January 19 to July 18, 2026), the company would sell the repurchased shares through centralized bidding transactions in an amount of no more than 1.854158 million shares. The plan was officially disclosed on December 24, 2025.

Details of the first sale: average price 127.11 yuan/share, accounting for 0.0098% of total share capital

According to the announcement, the company completed its first sale on March 30, 2026. The details are as follows:

Before this sale, the repurchase-dedicated securities account held 47.78183 million shares, accounting for 5.15% of total share capital; after the sale, the shareholding in the account decreased to 47.69083 million shares, and the shareholding ratio was adjusted to 5.14%. The announcement emphasized that this sale complies with the company’s pre-established plan and relevant regulations, including the “Guidelines No. 7 for Self-Regulatory Management of Listed Companies on the Shanghai Stock Exchange — Share Repurchases,” and others.

Follow-up risk warning: sale must comply with multiple trading restrictions

Rejing Bio stated that subsequent sales of shares will strictly comply with regulatory requirements, including: the declared price must not be the day’s trading limit decline price; orders must not be placed during the opening call auction and within the first half hour before the closing; the daily number of shares sold must not exceed 25% of the average daily trading volume of the 20 trading days prior to the pre-disclosure (excluding days where more than 200,000 shares are sold per day), and the total number of shares sold within any consecutive 90-day period must not exceed 1% of the company’s total share capital. The company said it will fulfill information disclosure obligations in a timely manner during the sale period and asks investors to pay attention to investment risks.

The Board of Beijing Rejing Biotechnology Co., Ltd. stated that this sale of repurchased shares is a reasonable arrangement made by the company based on market conditions and its own development needs, aiming to optimize the company’s capital structure and protect shareholders’ rights and interests. Subsequent progress will be disclosed in the form of announcements in a timely manner.

Disclaimer: The market involves risks; investments require caution. This article is automatically published by an AI model based on third-party databases and does not represent Sina Finance’s views. Any information appearing in this article is for reference only and does not constitute personal investment advice. If there is any discrepancy, please refer to the actual announcement. If you have any questions, please contact biz@staff.sina.com.cn.

Click to view the full text of the original announcement>>

Massive information and precise interpretation—right on the Sina Finance app

Editor: Xiao Lang Express